Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Swiss Rockets secures CoolMPS license from MGI — Plans western NGS launch

November 08, 2025

Swiss Rockets obtained an exclusive license to MGI/Complete Genomics’ CoolMPS sequencing chemistry for global commercialization outside the Asia‑Pacific region and announced plans to launch...

CMS unveils Generous model: Medicaid drug prices tied to international benchmarks

November 08, 2025

The Centers for Medicare & Medicaid Services’ Innovation Center launched the Generating Cost Reductions for U.S. Medicaid (GENEROUS) model, a voluntary five‑year pilot that will negotiate...

SGLT2 inhibitors cut kidney risk across eGFR and albuminuria levels — JAMA analysis

November 08, 2025

A landmark analysis presented in JAMA and at ASN Kidney Week assessed the benefits of sodium‑glucose cotransporter‑2 (SGLT2) inhibitors across patients with varying baseline glomerular filtration...

Pfizer wins Metsera... Novo ups the ante

November 08, 2025

Pfizer closed a winning bid for obesity biotech Metsera after a late-stage bidding contest with Novo Nordisk, putting roughly $10 billion on the table. Metsera accepted Pfizer’s increased offer,...

Intellia CRISPR trial halted after patient dies — liver signal under scrutiny

November 08, 2025

Intellia Therapeutics disclosed the death of an elderly patient in its Phase III MAGNITUDE trial of nexiguran ziclumeran (nex‑z), an in vivo CRISPR base‑editing therapy for transthyretin...

FDA expands national‑priority voucher awards — more drugs fast‑tracked

November 08, 2025

The FDA issued a second tranche of Commissioner’s National Priority Vouchers (CNPVs), adding six more therapies to a pilot program designed to accelerate review of drugs deemed in the national...

CMS launches 'GENERous' Medicaid drug model — prices tied to international benchmarks

November 08, 2025

The Centers for Medicare & Medicaid Services announced a five‑year voluntary model to lower Medicaid drug spending by negotiating prices tied to select international data. Under the Generating...

MIT LNP cuts mRNA dose 100‑fold — Nature Nanotech data

November 08, 2025

MIT researchers published a Nature Nanotechnology paper describing a new degradable cyclic amino ionizable lipid and LNP formulation that delivered an influenza mRNA vaccine at approximately...

China clears clinical long‑read sequencer; Swiss Rockets licenses CoolMPS

November 08, 2025

Berry Genomics received National Medical Products Administration Class III approval for PacBio’s Sequel II CNDx system — the first regulatory clearance for a clinical‑grade long‑read sequencer in...

SGLT2 class shows kidney benefits across populations — large analyses

November 08, 2025

A landmark nephrology analysis reinforced that sodium‑glucose cotransporter‑2 (SGLT2) inhibitors deliver kidney and cardiovascular benefits across patients with differing glomerular filtration...

Single‑cell consolidation — Qiagen buys Parse as 10x revenue softens

November 08, 2025

Qiagen agreed to acquire single‑cell specialist Parse Biosciences for up to $280 million, signaling continued consolidation as large instrument companies absorb high‑throughput single‑cell...

Braveheart funding surge — VCs back new biotech trio

November 08, 2025

Braveheart Bio closed a major financing and surfaced in multiple venture updates as new biotech launches attracted investor capital. Braveheart secured $185 million to advance a cardiometabolic...

Onchilles advances ELANE program — $25M round to push N17350

November 08, 2025

Onchilles Pharma published a landmark study on the ELANE pathway and announced $25 million in financing to advance N17350, a cancer‑killing enzyme–based therapeutic, toward first‑in‑human studies....

Intellia CRISPR patient dies — Phase 3 ATTR studies halted

November 08, 2025

Intellia Therapeutics disclosed that a patient dosed with its in vivo CRISPR candidate nexiguran ziclumeran (nex‑z) has died following severe liver injury, and the company paused dosing across its...

FDA expands National Priority Vouchers — six more drugs added

November 08, 2025

The FDA added six more therapies to its Commissioner’s National Priority Voucher (CNPV) program, expanding a pilot designed to accelerate review of drugs deemed in the national interest. The...

Pfizer and Novo Nordisk spar over Metsera — price approaches $10B

November 08, 2025

Two of the industry’s biggest players pushed a high‑stakes auction for obesity biotech Metsera this week, with Pfizer emerging the reported winner after upping its offer and valuing the company at...

China clears PacBio long‑read sequencer — Illumina export ban lifted

November 08, 2025

Pacific Biosciences said China’s National Medical Products Administration approved Berry Genomics’ Sequel II CNDx system — the world’s first regulatory clearance for a clinical‑grade long‑read...

SGLT2 inhibitors show kidney benefit across GFR and albuminuria

November 08, 2025

Large new analyses presented at recent nephrology forums and published in JAMA report that sodium‑glucose cotransporter‑2 (SGLT2) inhibitors provide kidney protection across a broad spectrum of...

MIT LNP cuts mRNA vaccine dose by 100x — new ionizable lipid

November 08, 2025

Researchers at MIT reported a next‑generation lipid nanoparticle (LNP) formulation that delivered an influenza mRNA vaccine at roughly 1/100th the dose required by current FDA‑approved LNP...

Qiagen buys Parse Biosciences — single‑cell tools consolidate

November 08, 2025

Qiagen agreed to acquire Seattle‑based Parse Biosciences for up to $280 million, folding a high‑throughput single‑cell library and automation platform into a larger public company. Parse...